While the test did not demonstrate improvements in overall pharmacologic management in the CPV scores, the test influenced important care decisions, as evidence by statistically significant increases in use of evidence-based pharmacologic treatments, specifically SGLT2 inhibitors and GLP1 receptor antagonists and recommendation of evidence-based non-pharmacologic treatments for patients with T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.